secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-07-14T10:04:48+00:00
Accession:  0001104659-26-083274
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience raises ~$93.9M in registered direct offering of 3.78M shares at $26.48/share
--------------------------------------------------------------------------------

- Offering of 3,776,436 shares of common stock at $26.48 per share, expected to close July 14, 2026.
- Net proceeds estimated at $93.9M after underwriting discounts and expenses.
- Proceeds to accelerate clinical development of ALTO-207, including additional Phase 3 trial for treatment-resistant depression.
- Joint book-runners: BofA Securities, Stifel, William Blair, Robert W. Baird; co-managers: JonesTrading, H.C. Wainwright.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/0001104659-26-083274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/tm2620328d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-083274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer